(0.11%) 5 254.35 points
(0.12%) 39 807 points
(-0.12%) 16 379 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(1.45%) $922.85
(0.36%) $0.927
(0.80%) $10.86
(0.11%) $0.792
(0.15%) $92.58
@ $37.88
Issued: 14 Feb 2024 @ 09:30
Return: -7.71%
Previous signal: Feb 13 - 09:30
Previous signal:
Return: 2.07 %
Live Chart Being Loaded With Signals
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency...
Stats | |
---|---|
Today's Volume | 231 800 |
Average Volume | 776 444 |
Market Cap | 1.66B |
EPS | $0 ( 2024-03-04 ) |
Next earnings date | ( $-1.040 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -6.83 |
ATR14 | $0.0180 (0.05%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-26 | Deck Kelly | Sell | 625 | Stock Option (right to buy) |
2024-03-26 | Deck Kelly | Sell | 396 | Stock Option (right to buy) |
2024-03-26 | Deck Kelly | Sell | 1 459 | Stock Option (right to buy) |
2024-03-26 | Deck Kelly | Sell | 416 | Stock Option (right to buy) |
2024-03-20 | Deck Kelly | Sell | 16 777 | Stock Option (right to buy) |
INSIDER POWER |
---|
55.56 |
Last 100 transactions |
Buy: 3 248 725 | Sell: 1 114 859 |
Volume Correlation
Inhibrx, Inc. Correlation
10 Most Positive Correlations | |
---|---|
BIOC | 0.929 |
NCBS | 0.92 |
FSFG | 0.918 |
SNPX | 0.911 |
SPFI | 0.906 |
BGFV | 0.905 |
EQBK | 0.905 |
SGMA | 0.904 |
PDBC | 0.903 |
ADTX | 0.903 |
10 Most Negative Correlations | |
---|---|
GDNR | -0.918 |
BTWN | -0.917 |
EZGO | -0.906 |
LUNA | -0.904 |
BRAC | -0.903 |
MLCO | -0.902 |
MLVF | -0.902 |
AVAC | -0.902 |
CBAY | -0.9 |
IIN | -0.899 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Inhibrx, Inc. Correlation - Currency/Commodity
Inhibrx, Inc. Financials
Annual | 2023 |
Revenue: | $1.80M |
Gross Profit: | $609 000 (33.83 %) |
EPS: | $-5.12 |
Q4 | 2023 |
Revenue: | $1.63M |
Gross Profit: | $1.34M (81.76 %) |
EPS: | $-1.730 |
Q3 | 2023 |
Revenue: | $119 000 |
Gross Profit: | $-185 000 (-155.46 %) |
EPS: | $-1.100 |
Q2 | 2023 |
Revenue: | $30 000.00 |
Gross Profit: | $-701 000 (-2 336.67 %) |
EPS: | $-1.080 |
Financial Reports:
No articles found.
Inhibrx, Inc.
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators